1. Changes in asthma maintenance therapy following the 2006 long-acting beta-agonist FDA drug warning;Winter;Clin Ther,2017
2. Food and Drug Administration. Communicating Risks and Benefits: An Evidence-Based User׳s Guide. http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm268078.htm. Updated July 2, 2015. Accessed February 4, 2017.
3. European Medicines Agency. Benefit-risk communication to medicines users. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500178511.pdf. Accessed February 1, 2017.
4. Nuclear Regulatory Commission. Effective risk communication. https://www.nrc.gov/docs/ML0406/ML040690412.pdf. Accessed February 1, 2017.
5. World Health Organization. Communication for Behavioral Impact. http://apps.who.int/iris/bitstream/10665/75170/1/WHO_HSE_GCR_2012.13_eng.pdf?ua=1. Accessed February 4, 2017.